Translate this page into:
Letters to Editor
doi:
10.4103/2278-330X.136821
Expected efficacy of HPV vaccine in prevention of cervix cancer in Thailand
1
Sanitation 1 Medical Academic Center, Bangkok, Thailand
2
Visiting Professor, Hainan Medical University, China,
3
Visiting Professor, Faculty of Medicine, University of Nis, Serbia
4
Adjunct Professor, Joseph Ayobabalola University, Nigeria
5
Professor, Senior Expert, Public Health Curriculum Surin Rajabhat University, Surin, Thailand
*Corresponding author: Dr. Beuy Joob. beuyjoob@hotmail.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
References
- Altinbas SK, Tapisiz OL. Human papillomavirus, vaccines, and protection from cervical cancer. Saudi Med J 2012;33:1270-7.
- Tomljenovic L, Spinosa JP, Shaw CA. Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe? Curr Pharm Des 2013;19:1466-87.
- Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial. Lancet 2009;373:1949-57.
- Songthap A, Pitisuttithum P, Kaewkungwal J, Fungladda W, Bussaratid V. Knowledge, attitudes, and acceptability of a human papilloma virus vaccine among students, parents and teachers in Thailand. Southeast Asian J Trop Med Public Health 2012;43:340-53.
- Termrungruanglert W, Havanond P, Khemapech N, Lertmaharit S, Pongpanich S, Khorprasert C, et al. Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries. Value Health 2012;15:S29-34.
- Chinchai T, Chansaenroj J, Swangvaree S, Junyangdikul P, Poovorawan Y. Prevalence of human papillomavirus genotypes in cervical cancer. Int J Gynecol Cancer 2012;22:1063-8.
- Henderson L, Clements A, Damery S, Wilkinson C, Austoker J, Wilson S, HPV Core Messages Writing Group. A false sense of security′? Understanding the role of the HPV vaccine on future cervical screening behaviour: A qualitative study of UK parents and girls of vaccination age. J Med Screen 2011;18:41-5.